A Phase 3 interventional study of M923 and Autoinjector in Rheumatoid Arthritis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.
Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 76th largest by enrollment, is one of 5 that started in 2016, is one of 36 in phase 3, and was the 73rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under Momenta Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Momenta Pharmaceuticals, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
90 studies in Arthritis, Rheumatoid by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 86 finished, 31 (36%) have results posted.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 64th largest by enrollment of the 75 interventional ones that give a count, is one of 3 that started in 2016, is one of 20 in phase 3, and was the 81st registered.
Johnson & Johnson’s Arthritis, Rheumatoid studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 90 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the usability of an auto-injector (AI) for the delivery of M923 in patients with rheumatoid arthritis (RA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
Biological: M923 · Device: Autoinjector
Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Also known as: Adalimumab
Subcutaneous administration
Usability of the Auto-injector (AI) at Week 4
The primary usability measure was the participant rating captured in the PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules at Week 4. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
Time frame: Week 4
Number of Participants With Successful Injections as Assessed by the Observer at Week 4
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
Time frame: Week 4
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 4
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
Time frame: Week 4
Usability of the Auto-injector at Baseline
The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Baseline. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
Time frame: Baseline (Day 1)
Usability of the Auto-injector at Week 2
The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Week 2. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
Time frame: Week 2
Number of Participants With Successful Injections as Assessed by the Observer at Baseline
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
Time frame: Baseline (Day 1)
Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
Time frame: Baseline (Day 1)
Number of Participants With Successful Injections as Assessed by the Observer at Week 2
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
Time frame: Week 2
Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 2
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
Time frame: Week 2
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Hematology, clinical chemistry, and urinalysis clinical laboratory parameters were assessed. The hematology panel consisted of complete blood count, hemoglobin, hematocrit, mean cell volume, total leukocytes, and platelet counts. The clinical chemistry panel consisted of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase, creatine kinase, C-reactive protein, cholesterol, triglycerides, total protein, sodium, potassium, chloride, blood urea nitrogen, creatinine, albumin, calcium, phosphate, glucose, glycosylated hemoglobin, uric acid, and bicarbonate. The urinalysis panel consisted of leucocytes, protein, bilirubin, urobilinogen, glucose, ketones, blood pH, nitrite, and specific gravity. Clinical significance was assessed by the Investigator.
Time frame: Baseline; 32 Weeks
Number of Participants With Vital Signs Outside the Expected Range
Vital signs included respiratory rate, body temperature, pulse rate, and systolic and diastolic blood pressure.
Time frame: 32 Weeks
Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings
Clinical significance was assessed by the Investigator.
Time frame: Baseline; 32 Weeks
Number of Participants With Adverse Events Leading to Premature Study Withdrawal
The number of participants who had an adverse event that led to premature study withdrawal was assessed.
Time frame: 32 Weeks
Number of Participants With Treatment-emergent Injection Site Reactions
An injection site reaction is defined as pain, tenderness, erythema/redness, induration/swelling, and other. If an injection site reaction was observed, a physician was to characterize and document the reaction as an adverse event (AE). Treatment-emergent adverse events (TEAEs) are defined as AEs that started or worsened in severity on or after the first dose of study medication, until study completion/withdrawal or within 30 days following the last treatment for early withdrawn participants.
Time frame: 32 Weeks
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of Anti-drug Antibodies (ADAs) at Baseline
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Baseline (Day 1)
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 4
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 4
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 12
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 12
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at Week 24
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 24
Immunogenicity of M923 Assessed as the Number of Participants With Evidence of Seroconversion as Measured by Titer of ADAs at the Safety Follow-Up Visit
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Safety Follow-Up Visit (32 Weeks)
Immunogenicity of M923 Assessed as the Number of Participants With Neutralizing Anti-drug Antibodies (nADAs) at Baseline
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Baseline (Day 1)
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 4
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 4
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 12
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 12
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at Week 24
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Week 24
Immunogenicity of M923 Assessed as the Number of Participants With nADAs at the Safety Follow-Up Visit
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
Time frame: Safety Follow-Up Visit (32 Weeks)
A total of 51 participants were screened, and 33 participants were enrolled in the study.
| Milestone | M923 40 mg |
|---|---|
| Started | 33 |
| Completed | 28 |
| Not completed | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Did not meet criteria at week 14 | 1 |
The primary usability measure was the participant rating captured in the PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules at Week 4. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
| Scores on a scale | M923 40 mg |
|---|---|
| Feelings about injections: PRE | 8.15 ± 2.049 |
| Feelings about injections: POST | 8.17 ± 1.930 |
| Self-image: POST | 9.27 ± 2.061 |
| Self-confidence: PRE | 8.12 ± 2.183 |
| Self-confidence: POST | 8.39 ± 2.287 |
| Pain/skin reactions during/after injection: POST | 9.33 ± 0.630 |
| Pain during/after injection: POST | 8.76 ± 1.234 |
| Skin reactions: POST | 9.90 ± 0.301 |
| Ease of use of the AI: POST | 8.72 ± 2.072 |
| Satisfaction with self-injection: PRE | 8.39 ± 1.887 |
| Satisfaction with self-injection: POST | 8.89 ± 1.369 |
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
| Participants | M923 40 mg |
|---|---|
| Successfully completed P7, P10, and P11 | 31 |
| Successfully completed all 14 instructions | 31 |
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 4 | 31 |
The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Baseline. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
| Scores on a scale | M923 40 mg |
|---|---|
| Feelings about injections: PRE | 7.20 ± 2.810 |
| Feelings about injections: Post | 7.98 ± 2.507 |
| Self-image: POST | 9.52 ± 1.357 |
| Self-confidence: PRE | 6.34 ± 3.218 |
| Self-confidence: POST | 7.96 ± 2.535 |
| Pain/skin reactions: POST | 8.99 ± 0.865 |
| Pain during/after injection: POST | 8.15 ± 1.591 |
| Skin reaction: POST | 9.84 ± 0.326 |
| Ease of use of the AI: POST | 8.26 ± 1.956 |
| Satisfaction with AI: PRE | 7.98 ± 2.365 |
| Satisfaction with AI: POST | 8.57 ± 1.490 |
The usability measure was the participant rating captured in the PRE- and POST- SIAQ modules at Week 2. The PRE-SIAQ module is a 7-item questionnaire that investigates feelings about injections, self-confidence (regarding self-administration), and satisfaction with self-injection. The POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions during or after injection (injection-site reactions), ease of use of the self-injection device, and satisfaction with self-injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scale, where a score of 1 corresponds to a participant's worst experience and a score of 5 (or 6) corresponds to a participant's best experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item.
| Scores on a scale | M923 40 mg |
|---|---|
| Feelings about injections: PRE | 7.82 ± 2.294 |
| Feelings about injections: POST | 8.06 ± 2.057 |
| Self-image: POST | 9.60 ± 1.307 |
| Self-confidence: PRE | 7.77 ± 2.311 |
| Self-confidence: POST | 8.09 ± 2.319 |
| Pain/skin reactions: POST | 9.22 ± 0.747 |
| Pain during/after injection: POST | 8.55 ± 1.490 |
| Skin reactions: POST | 9.89 ± 0.213 |
| Ease of use of the AI: POST | 8.49 ± 2.098 |
| Satisfaction with AI: PRE | 8.39 ± 1.773 |
| Satisfaction with AI: POST | 8.65 ± 1.448 |
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
| Participants | M923 40 mg |
|---|---|
| Successfully completed P7, P10, and P11 | 31 |
| Successfully completed all 14 instructions | 31 |
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Hazard-free Injections as Assessed by the Observer at Baseline | 31 |
Observers assessed usability by using a self-injection checklist. Self-injection assessment was coded as successful if categories P7 (removed protective needle cap from auto-injector), P10 (press down on auto-injector to insert the needle into the skin), and P11 (held auto-injector pressed fully down through second "click" sound) were checked as "yes."
| Participants | M923 40 mg |
|---|---|
| Successfully completed P7, P10, and P11 | 31 |
| Successfully completed all 14 instructions | 31 |
Observers assessed usability by using a potential hazard checklist. If all potential hazards in the checklist were checked as "no," the assessment was coded as hazard free.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Hazard-free Injections as Assessed by the Observer at Week 2 | 31 |
Hematology, clinical chemistry, and urinalysis clinical laboratory parameters were assessed. The hematology panel consisted of complete blood count, hemoglobin, hematocrit, mean cell volume, total leukocytes, and platelet counts. The clinical chemistry panel consisted of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, lactate dehydrogenase, creatine kinase, C-reactive protein, cholesterol, triglycerides, total protein, sodium, potassium, chloride, blood urea nitrogen, creatinine, albumin, calcium, phosphate, glucose, glycosylated hemoglobin, uric acid, and bicarbonate. The urinalysis panel consisted of leucocytes, protein, bilirubin, urobilinogen, glucose, ketones, blood pH, nitrite, and specific gravity. Clinical significance was assessed by the Investigator.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 |
Vital signs included respiratory rate, body temperature, pulse rate, and systolic and diastolic blood pressure.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Vital Signs Outside the Expected Range | 13 |
Clinical significance was assessed by the Investigator.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Clinically Significant Changes in Twelve-lead Electrocardiogram (ECG) Findings | 0 |
The number of participants who had an adverse event that led to premature study withdrawal was assessed.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Adverse Events Leading to Premature Study Withdrawal | 2 |
An injection site reaction is defined as pain, tenderness, erythema/redness, induration/swelling, and other. If an injection site reaction was observed, a physician was to characterize and document the reaction as an adverse event (AE). Treatment-emergent adverse events (TEAEs) are defined as AEs that started or worsened in severity on or after the first dose of study medication, until study completion/withdrawal or within 30 days following the last treatment for early withdrawn participants.
| Participants | M923 40 mg |
|---|---|
| Number of Participants With Treatment-emergent Injection Site Reactions | 1 |
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall ADA/negative predose | 6 |
| Overall ADA/positive predose | 27 |
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall ADA/negative | 6 |
| Overall ADA/positive | 26 |
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall ADA/negative | 5 |
| Overall ADA/positive | 18 |
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall ADA/negative | 5 |
| Overall ADA/positive | 17 |
A participant was considered to have developed ADAs if a confirmed positive result was observed at any time during the treatment period post-dose (irrespective of titer value). Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall ADA/negative | 6 |
| Overall ADA/positive | 25 |
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall nADA/negative | 26 |
| Overall nADA/positive | 7 |
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall nADA/negative | 26 |
| Overall nADA/positive | 6 |
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall nADA/negative | 17 |
| Overall nADA/positive | 6 |
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall nADA/negative | 18 |
| Overall nADA/positive | 4 |
A participant was considered to have developed nADAs if a confirmed positive result was observed at any time during the treatment period post-dose. Samples were collected predose (prior to administering investigational product) and before any hematology/chemistry samples were drawn at that visit.
| Participants | M923 40 mg |
|---|---|
| Overall nADA/negative | 24 |
| Overall nADA/positive | 7 |
Collected over From the date of Screening until the Safety Follow-Up Visit (approximately 32 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| M923 40 mg | 0/33 (0%) | 2/33 (6.1%) | 31/33 (93.9%) |
| Event | M923 40 mg |
|---|---|
| Duodenal ulcer perforationGastrointestinal disorders | 1/33 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/33 |
| SyncopeNervous system disorders | 1/33 |
| Event | M923 40 mg |
|---|---|
| Injection site painGeneral disorders | 27/33 |
| Injection site erythemaGeneral disorders | 10/33 |
| Injection site bruisingGeneral disorders | 5/33 |
| Injection site swellingGeneral disorders | 5/33 |
| Injection site coldnessGeneral disorders | 4/33 |
| Injection site pruritusGeneral disorders | 4/33 |
| Administrative site painGeneral disorders | 2/33 |
| Injection site indurationGeneral disorders | 2/33 |
| NasopharyngitisInfections and infestations | 2/33 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 2/33 |
Safety Analysis Set: all participants who received study medication
| Age, Continuous(years) | M923 40 mg |
|---|---|
| Mean | 58.2 ± 9.82 |
| Sex: Female, Male(Participants) | M923 40 mg |
|---|---|
| Female | 28 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | M923 40 mg |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | M923 40 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 29 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 1 year 2 months after primary completion. A results delay was requested in Feb 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Momenta Pharmaceuticals, Inc. →